30 research outputs found
Targeted Simplification Versus Antipseudomonal Broad-Spectrum Beta-Lactams in Patients With Bloodstream Infections Due to Enterobacteriaceae (SIMPLIFY): A Study Protocol for a Multicentre, Open-Label, Phase III Randomised, Controlled, Non-Inferiority Clinical Trial.
Introduction Within the context of antimicrobial
stewardship programmes, de-escalation of antimicrobial
therapy is one of the proposed strategies for reducing the
unnecessary use of broad-spectrum antibiotics (BSA). The
empirical treatment of nosocomial and some healthcare-
associated bloodstream infections (BSI) frequently
includes a beta-lactam with antipseudomonal activity as
monotherapy or in combination with other drugs, so there
is a great opportunity to optimise the empirical therapy
based on microbiological data. De-escalation is assumed
as standard of care for experts in infectious diseases.
However, it is less frequent than it would desirable.
Methods and analysis The SIMPLIFY trial is a
multicentre, open-label, non-inferiority phase III
randomised controlled clinical trial, designed as a
pragmatic ‘real-practice’ trial. The aim of this trial is to
demonstrate the non-inferiority of de-escalation from
an empirical beta-lactam with antipseudomonal activity
to a targeted narrow-spectrum antimicrobial in patients
with BSI due to Enterobacteriaceae. The primary outcome
is clinical cure, which will be assessed at the test of
cure visit. It will be conducted at 19 Spanish public and
university hospitals.
Ethics and dissemination Each participating centre has obtained the approval of the ethics review committee, the agreement of the directors of the institutions and authorisation from the Spanish Regulatory Agency (Agencia Española del Medicamento y Productos Sanitarios). Data will be presented at international conferences and published in peer-reviewed journals.
[Discussion] Strategies to reduce the use of BSA should be a priority. Most of the studies that support de-escalation are observational, retrospective and heterogeneous. A recent Cochrane review stated that well-designed clinical trials should be conducted to assess the safety and efficacy of de-escalation.Instituto de Salud Carlos III (ISCIII): PI15/00439, integrado en el Plan Nacional de I+D+i 2013-2016 y cofinanciado por la Unión Europea (ERDF/ESF, “Investing in your future”)
Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): protocol for a randomised, pragmatic trial
Introduction: Alternatives to carbapenems are needed in the treatment of third-generation cephalosporin-resistant Enterobacterales (3GCR-E). Temocillin is a suitable candidate, but comparative randomised studies are lacking. The objective is to investigate if temocillin is non-inferior to carbapenems in the targeted treatment of bacteraemia due to 3GCR-E.
Methods and analysis: Multicentre, open-label, randomised, controlled, pragmatic phase 3 trial. Patients with bacteraemia due to 3GCR-E will be randomised to receive intravenously temocillin (2 g three times a day) or carbapenem (meropenem 1 g three times a day or ertapenem 1 g once daily). The primary endpoint will be clinical success 7–10 days after end of treatment with no recurrence or death at day 28. Adverse events will be collected; serum levels of temocillin will be investigated in a subset of patients. For a 10% non-inferiority margin, 334 patients will be included (167 in each study arm). For the primary analysis, the absolute difference with one-sided 95% CI in the proportion of patients reaching the primary endpoint will be compared in the modified intention-to-treat population.
Ethics and dissemination: The study started after approval of the Spanish Regulatory Agency and the reference institutional review board. Data will be published in peer-reviewed journals.
Trial registration number: NCT04478721.Instituto de Salud Carlos III ICI19/00093Ministerio de Economía, Industria y Competitividad y Fondos FEDER RD16/0016/0001, 0002, 0004, 0008, 0009, 0010, 0011, 0013, 001
Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections A Randomized Clinical Trial
Importance The consumption of broad-spectrum drugs has increased as a consequence of the spread of multidrug-resistant (MDR) Escherichia coli. Finding alternatives for these infections is critical, for which some neglected drugs may be an option.
Objective To determine whether fosfomycin is noninferior to ceftriaxone or meropenem in the targeted treatment of bacteremic urinary tract infections (bUTIs) due to MDR E coli.
Design, Setting, and Participants This multicenter, randomized, pragmatic, open clinical trial was conducted at 22 Spanish hospitals from June 2014 to December 2018. Eligible participants were adult patients with bacteremic urinary tract infections due to MDR E coli; 161 of 1578 screened patients were randomized and followed up for 60 days. Data were analyzed in May 2021.
Interventions Patients were randomized 1 to 1 to receive intravenous fosfomycin disodium at 4 g every 6 hours (70 participants) or a comparator (ceftriaxone or meropenem if resistant; 73 participants) with the option to switch to oral fosfomycin trometamol for the fosfomycin group or an active oral drug or parenteral ertapenem for the comparator group after 4 days.
Main Outcomes and Measures The primary outcome was clinical and microbiological cure (CMC) 5 to 7 days after finalization of treatment; a noninferiority margin of 7% was considered.
Results Among 143 patients in the modified intention-to-treat population (median [IQR] age, 72 [62-81] years; 73 [51.0%] women), 48 of 70 patients (68.6%) treated with fosfomycin and 57 of 73 patients (78.1%) treated with comparators reached CMC (risk difference, −9.4 percentage points; 1-sided 95% CI, −21.5 to ∞ percentage points; P = .10). While clinical or microbiological failure occurred among 10 patients (14.3%) treated with fosfomycin and 14 patients (19.7%) treated with comparators (risk difference, −5.4 percentage points; 1-sided 95% CI, −∞ to 4.9; percentage points; P = .19), an increased rate of adverse event–related discontinuations occurred with fosfomycin vs comparators (6 discontinuations [8.5%] vs 0 discontinuations; P = .006). In an exploratory analysis among a subset of 38 patients who underwent rectal colonization studies, patients treated with fosfomycin acquired a new ceftriaxone-resistant or meropenem-resistant gram-negative bacteria at a decreased rate compared with patients treated with comparators (0 of 21 patients vs 4 of 17 patients [23.5%]; 1-sided P = .01).
Conclusions and Relevance This study found that fosfomycin did not demonstrate noninferiority to comparators as targeted treatment of bUTI from MDR E coli; this was due to an increased rate of adverse event–related discontinuations. This finding suggests that fosfomycin may be considered for selected patients with these infections
Statistical analysis plan. Study protocol for a randomized clinical trial to assess 7 versus 14-days of treatment for Pseudomonas aeruginosa bloodstream infections (SHORTEN-2 trial)
Efficacy and safety of 7 versus 14 days of antibiotic treatment for Pseudomonas aeruginosa bacteraemia: a multicentre, randomized clinical trial (SHORTEN-2) with a DOOR/RADAR analysis.Peer reviewe
Full-length study protocol (Spanish). Study protocol for a randomized clinical trial to assess 7 versus 14-days of treatment for Pseudomonas aeruginosa bloodstream infections (SHORTEN-2 trial)
Eficacia y seguridad de 7 versus 14 días de tratamiento antibiótico para la bacteriemia producida por Pseudomonas aeruginosa: un ensayo clínico multicéntrico, aleatorizado (SHORTEN-2) con un análisis DOOR/RADAR.Peer reviewe
List of participating centers. Study protocol for a randomized clinical trial to assess 7 versus 14-days of treatment for Pseudomonas aeruginosa bloodstream infections (SHORTEN-2 trial)
S1 File. List of participating centers.Peer reviewe
Full-length study protocol (English). Study protocol for a randomized clinical trial to assess 7 versus 14-days of treatment for Pseudomonas aeruginosa bloodstream infections (SHORTEN-2 trial)
Efficacy and safety of 7 versus 14 days of antibiotic treatment for Pseudomonas aeruginosa bacteraemia: a multicentre, randomized clinical trial (SHORTEN-2) with a DOOR/RADAR analysis.Peer reviewe
Results of the survey among participating centers regarding diagnostic and clinical routines for the management of BSI-PA
S4 File. Results of the survey among participating centers regarding diagnostic and clinical routines for the management of BSI-PAPeer reviewe
Definitions for main trial variables. Study protocol for a randomized clinical trial to assess 7 versus 14-days of treatment for Pseudomonas aeruginosa bloodstream infections (SHORTEN-2 trial)
S2 File. Definitions for main trial variables.Peer reviewe
Efficacy and safety of a booster dose of influenza vaccination in solid organ transplant recipients, TRANSGRIPE 1-2: study protocol for a multicenter, randomized, controlled clinical trial
BACKGROUND: Despite administration of annual influenza
vaccination, influenza-associated complications in transplant
recipients continue to be an important cause of hospitalization
and death. Although influenza vaccination has been proven to be
the most effective measure to reduce influenza infection after
transplantation, transplant recipients are still vulnerable to
influenza infections, with lower serological responses to
vaccination compared to the general population. In order to
assess the efficacy and safety of an alternative immunization
scheme for solid organ transplant recipients, the TRANSGRIPE1-2
Study Group aimed to test a booster dose administration 5 weeks
after the standard vaccination. The primary objective of this
trial was to compare short-term and long-term neutralizing
antibody immunogenicity of a booster dose of influenza
vaccination to the standard single-dose immunization scheme.
Secondary objectives included the evaluation of the efficacy
and/or safety, cellular immune response, incidence of influenza
infection, graft rejection, retransplant and mortality rates.
METHODS/DESIGN: This phase III, randomized, controlled,
open-label clinical trial was conducted between October 2012 and
December 2013 in 12 Spanish public referral hospitals. Solid
organ transplant recipients (liver, kidney, heart or lung),
older than 16 years of age more than 30 days after
transplantation were eligible to participate. Patients (N = 514)
were stratified 1:1 by center, type of organ and time after
transplantation and who either received the standard single dose
(n = 257) or were treated according to a novel influenza
vaccination schedule comprising the administration of a booster
dose 5 weeks after standard vaccination (n = 254).
Seroconversion rates were measured as a determinant of
protection against influenza (main outcome). Efficacy and safety
outcomes were followed until 1 year after influenza vaccination
with assessment of short-term (0, 5, 10 and 15 weeks) and
long-term (12 months) results. Intention-to-treat, per-protocol
and safety analyses will be performed. DISCUSSION: This trial
will increase knowledge about the safety and efficacy of a
booster dose of influenza vaccine in solid organ transplant
recipients. At the time the manuscript was submitted for
publication, trial recruitment was closed with a total of 499
participants included during a 2-month period (within the
seasonal influenza vaccination campaign). TRIAL REGISTRATION:
ClinicalTrials.gov Identifier: NCT01761435 (registered 13
December 2012). EudraCT Identifier: 2011-003243-21 (registered 4
July 2011)